Summary & Overview
CPT 96567: Photodynamic Therapy for Precancerous Skin Cells
CPT code 96567 is a nationally recognized billing code for photodynamic therapy, specifically involving the external application of light to destroy precancerous skin cells. This procedure is widely used in dermatology offices and outpatient clinics to address conditions such as actinic keratosis and carcinoma in situ. The code is reported once per day, reflecting its use in targeted, light-based treatments for skin abnormalities.
Major payers covering this service include Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare. The publication provides a comprehensive overview of payer coverage, clinical indications, and relevant policy updates for photodynamic therapy procedures. Readers will gain insights into coding benchmarks, typical sites of service, and the clinical context for the use of CPT 96567. The summary also highlights associated diagnoses and related codes, offering a clear understanding of how this procedure fits into broader dermatology practice and reimbursement frameworks.
This article is intended for healthcare professionals, billing specialists, and policy analysts seeking up-to-date information on photodynamic therapy billing and coverage. It emphasizes the importance of accurate coding and payer awareness in delivering effective dermatologic care.
CPT Code Overview
CPT 96567 represents photodynamic therapy by external application of light to destroy precancerous cells. This procedure is typically performed in a dermatology office or outpatient clinic setting and is reported once per day. As a part of the photodynamic therapy procedures service line, it is used to treat patients with skin conditions that require targeted destruction of abnormal cells using light-based technology. The code is designed for external application and is commonly utilized in clinical dermatology practices.
Clinical & Coding Specifications
Clinical Context
A patient presents to a dermatology office with multiple rough, scaly patches on sun-exposed areas of the skin, such as the face or lips. The dermatologist diagnoses actinic keratosis or carcinoma in situ based on clinical examination and, if needed, biopsy. The provider determines that photodynamic therapy is appropriate to destroy precancerous cells. The procedure involves applying a photosensitizing agent to the affected skin, followed by exposure to a specific wavelength of light. The service is reported once per day using CPT code 96567. The workflow includes patient evaluation, informed consent, application of the agent, light activation, and post-procedure care. Repeat treatments may be performed as clinically indicated.
Coding Specifications
-
Modifiers:
- Modifier
59: Used to indicate a distinct procedural service, such as when photodynamic therapy is performed separately from other procedures on the same day. - Modifier
76: Used when the same photodynamic therapy procedure is repeated by the same physician or qualified health care professional.
- Modifier
-
Provider Taxonomies:
Taxonomy Code Specialty Name 207N00000XDermatology Physician 207ND0101XMOHS-Micrographic Surgery Physician 207NS0135XProcedural Dermatology Physician
These taxonomies represent providers specializing in dermatologic procedures, including photodynamic therapy.
Related Diagnoses
-
L57.0: Actinic keratosis- Actinic keratosis is a common indication for photodynamic therapy, as it represents precancerous skin lesions caused by chronic sun exposure.
-
D04.0: Carcinoma in situ of skin of lip- This diagnosis refers to early-stage skin cancer confined to the lip, suitable for non-invasive treatments like photodynamic therapy.
-
D04.39: Carcinoma in situ of skin of other parts of face- Similar to
D04.0, this code covers carcinoma in situ on facial skin, which can be treated with photodynamic therapy.
- Similar to
-
D03.0: Melanoma in situ of lip- Melanoma in situ is an early form of melanoma limited to the epidermis; photodynamic therapy may be considered in select cases.
-
L57.8: Other specified skin changes due to chronic exposure to nonionizing radiation- This code includes skin changes from chronic sun exposure, which may be managed with photodynamic therapy to prevent progression.
Related CPT Codes
96574: Photodynamic therapy with removal of hyperkeratotic (hardened, dry, scaly) skin lesions followed by photodynamic therapy
96574 is related to 96567 as it includes an additional step of removing hyperkeratotic lesions before the photodynamic therapy. In clinical workflow, 96574 may be used when patients have thick, scaly lesions that require removal prior to light activation, whereas 96567 is used for standard photodynamic therapy without lesion removal. These codes are alternatives depending on the patient's skin condition; they are not typically billed together for the same site on the same day.
National Reimbursement Benchmarks
National mean rates for CPT code 96567 show that Blue Cross Blue Shield, Cigna, UnitedHealth Group, and BUCA (the average commercial benchmark) all reimburse at higher levels than Medicare. The BUCA mean rate is $180.61, which is $45.13 above the Medicare mean rate of $135.48. Cigna and UnitedHealth Group have the highest mean rates among commercial payers, both exceeding $219.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Medicare has the tightest range at $20.00, indicating relatively consistent reimbursement. In contrast, Cigna and UnitedHealth Group exhibit the widest dispersions, with ranges of $125.67 and $128.50 respectively, reflecting greater variability in commercial rates. Aetna and BUCA also show moderate dispersion, while Blue Cross Blue Shield's range is $68.00.
The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.